Biofrontera AG

  • WKN: 604611
  • ISIN: DE0006046113
  • Land: Deutschland

Nachricht vom 16.04.2020 | 16:00

Biofrontera AG: Biofrontera AG to propose resolution for ordinary capital increase to the Annual General Meeting

Biofrontera AG / Key word(s): Capital Increase
Biofrontera AG: Biofrontera AG to propose resolution for ordinary capital increase to the Annual General Meeting

16-Apr-2020 / 16:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad-hoc Release pursuant to Art. 17 MAR

Biofrontera AG to propose resolution for ordinary capital increase to the Annual General Meeting

Leverkusen, Germany, April 16, 2020 - The Annual General Meeting of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) shall be held on May 28, 2020. Today, the Company has decided to propose to the Annual General Meeting a resolution for an ordinary capital increase. This proposed resolution includes but is not limited to the following contents:

- The Company's share capital shall be increased by up to EUR 8,969,870 by issuing up to 8,969,870 new registered no-par value shares, each with a notional interest in the share capital of EUR 1.00 ("New Shares"), against cash contributions.

- The subscription right will be granted to the shareholders indirectly based on a 5 : 1 ratio and at a subscription price to be determined.

- The subscription price will be dutifully determined by a resolution of the Management Board (Vorstand) with the approval of the Supervisory Board (Aufsichtsrat), taking into account market conditions, however, it must not be lower than the minimum amount pursuant to Section 9 (1) of the German Stock Corporation Act (AktG).

Further details will be published in the convocation of the Annual General Meeting, which will be published in the Federal Gazette.

The proceeds from the capital increase will be used to continue financing clinical studies for the further development of Ameluz(R), for sales and marketing expenses of Ameluz(R) particularly in the US and to cover costs of the current business operations.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

Contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
E-mail: ir@biofrontera.com


16-Apr-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

Fachkonferenz Beteiligungsgesellschaften, 15.07.2020

Fachkonferenz Consumer / Leisure, 16.07.2020

Die Konferenzen finden aufgrund der aktuellen Situation nicht in den Räumen der Börse München statt, sondern als Online-Konferenz.

GBC-Fokusbox

Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv

Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.